These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 11274895)

  • 21. Novel GPCRs and their endogenous ligands: expanding the boundaries of physiology and pharmacology.
    Marchese A; George SR; Kolakowski LF; Lynch KR; O'Dowd BF
    Trends Pharmacol Sci; 1999 Sep; 20(9):370-5. PubMed ID: 10462760
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Affinity-based screening techniques: their impact and benefit to increase the number of high quality leads.
    Bergsdorf C; Ottl J
    Expert Opin Drug Discov; 2010 Nov; 5(11):1095-107. PubMed ID: 22827747
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design and implementation of high throughput screening assays.
    Macarrón R; Hertzberg RP
    Methods Mol Biol; 2002; 190():1-29. PubMed ID: 12029816
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries.
    Inglese J; Auld DS; Jadhav A; Johnson RL; Simeonov A; Yasgar A; Zheng W; Austin CP
    Proc Natl Acad Sci U S A; 2006 Aug; 103(31):11473-8. PubMed ID: 16864780
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Streamlining lead discovery by aligning in silico and high-throughput screening.
    Davies JW; Glick M; Jenkins JL
    Curr Opin Chem Biol; 2006 Aug; 10(4):343-51. PubMed ID: 16822701
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Functional human 5-HT6 receptor assay for high throughput screening of chemical ligands and binding proteins.
    Kim HJ; Yun HM; Kim T; Nam G; Roh EJ; Kostenis E; Choo HY; Pae AN; Rhim H
    Comb Chem High Throughput Screen; 2008 May; 11(4):316-24. PubMed ID: 18473741
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Advances in improving the quality and flexibility of compound management.
    Janzen WP; Popa-Burke IG
    J Biomol Screen; 2009 Jun; 14(5):444-51. PubMed ID: 19483148
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The application of high-throughput screening to novel lead discovery.
    Kenny BA; Bushfield M; Parry-Smith DJ; Fogarty S; Treherne JM
    Prog Drug Res; 1998; 51():245-69. PubMed ID: 9949864
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fragment-based approach to drug lead discovery: overview and advances in various techniques.
    Fattori D; Squarcia A; Bartoli S
    Drugs R D; 2008; 9(4):217-27. PubMed ID: 18588353
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The inadequacy of the reductionist approach in discovering new therapeutic agents against complex diseases.
    Duval MX
    Exp Biol Med (Maywood); 2018 Aug; 243(12):1004-1013. PubMed ID: 30089398
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recent progress in biomolecular engineering.
    Ryu DD; Nam DH
    Biotechnol Prog; 2000; 16(1):2-16. PubMed ID: 10662483
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Aptamers as reagents for high-throughput screening.
    Green LS; Bell C; Janjic N
    Biotechniques; 2001 May; 30(5):1094-6, 1098, 1100 passim. PubMed ID: 11355345
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Discovery of novel targets with high throughput RNA interference screening.
    Kassner PD
    Comb Chem High Throughput Screen; 2008 Mar; 11(3):175-84. PubMed ID: 18336211
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The use of constitutively active GPCRs in drug discovery and functional genomics.
    Chalmers DT; Behan DP
    Nat Rev Drug Discov; 2002 Aug; 1(8):599-608. PubMed ID: 12402500
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Smart screening: approaches to efficient HTS.
    Engels MF; Venkatarangan P
    Curr Opin Drug Discov Devel; 2001 May; 4(3):275-83. PubMed ID: 11560058
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Orphan G-protein-coupled receptors: the next generation of drug targets?
    Wilson S; Bergsma DJ; Chambers JK; Muir AI; Fantom KG; Ellis C; Murdock PR; Herrity NC; Stadel JM
    Br J Pharmacol; 1998 Dec; 125(7):1387-92. PubMed ID: 9884064
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rediscovering natural products as a source of new drugs.
    Koehn FE; Carter GT
    Discov Med; 2005 Apr; 5(26):159-64. PubMed ID: 20704903
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Affinity-based screening techniques for enhancing lead discovery.
    Comess KM; Schurdak ME
    Curr Opin Drug Discov Devel; 2004 Jul; 7(4):411-6. PubMed ID: 15338950
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Selection criteria for drug-like compounds.
    Muegge I
    Med Res Rev; 2003 May; 23(3):302-21. PubMed ID: 12647312
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HTS technologies in biopharmaceutical discovery.
    Wu G; Doberstein SK
    Drug Discov Today; 2006 Aug; 11(15-16):718-24. PubMed ID: 16846799
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.